Search clinical trials for: Combination of Fruquintinib and Camrelizumab

Total 146494 results

The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Unresectable/Metastatic Colorectal Cancer

China
Chinese PLA General Hospital
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Rui-hua Xu, MD, PhD

Not yet recruiting

A Phase II Study of Surufatinib Combined With PD-L1 and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Advanced Pancreatic Cancer

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; Peking University Shougang Hospital

Withdrawn

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Progression | Pediatric Cancer | Effect of Drugs

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Peking University People's Hospital

Completed

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Soft Tissue Sarcoma | Bone Sarcoma | Refractory Tumor

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Junjie Peng

Not yet recruiting

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Colorectal Cancer Metastatic

China
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Henan Provincial People's Hospital

Not yet recruiting

Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study (NSCLC)

Nsclc
Wuhan Union Hospital, China

Not yet recruiting

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Metastatic Colorectal Cancer

China
Wuhan Union Hospital, China

Recruiting

Fruquintinib in the Cross-line Treatment of Refractory mCRC

Metastatic Colorectal Cancer | Fruquintinib

China
Peking Union Medical College Hospital

Recruiting

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Radioactive Iodine-refractory Differentiated Thyroid Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma

China
Huashan Hospital
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Sunstem Biotechnology Co., Ltd.

Recruiting

Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Weijian Guo

Not yet recruiting

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Locally Advanced Rectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

Gastric Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer

Gastric Cancer

China
Zhejiang Cancer Hospital

Unknown

A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

Colorectal Cancer

China
Bronx VA Medical Center

Completed

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol

Hypercholesterolemia

United States
Fujian Medical University

Completed

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Neoadjuvant Therapy | Advanced Gastric Cancer | Multi-omics Analysis

China
Zhejiang Cancer Hospital

Not yet recruiting

Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Xingchen Peng
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

Head and Neck Squamous Cell Carcinoma

China
Guangxi Medical University

Recruiting

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer | Fruquintinib | SOX

China
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
Fudan University

Not yet recruiting

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Cancer

China
Henan Cancer Hospital

Recruiting

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Gastric Cancer

China
Fudan University

Active, not recruiting

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Triple-Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
Wuhan Union Hospital, China

Recruiting

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Colorectal Adenocarcinoma

China
Wuhan Union Hospital, China

Active, not recruiting

Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer

Rectal Cancer | Radiotherapy | Immunotherapy

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Intrahepatic Cholangiocarcinoma

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
Fudan University
Shanxi Province Cancer Hospital

Recruiting

Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

Advanced Colorectal Carcinoma

China

3

Subscribe